Literature DB >> 23079657

STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation.

Hazel Tye1, Catherine L Kennedy, Meri Najdovska, Louise McLeod, William McCormack, Norman Hughes, Anouk Dev, William Sievert, Chia Huey Ooi, Tomo-o Ishikawa, Hiroko Oshima, Prithi S Bhathal, Andrew E Parker, Masanobu Oshima, Patrick Tan, Brendan J Jenkins.   

Abstract

Gastric cancer (GC) is associated with chronic inflammation; however, the molecular mechanisms promoting tumorigenesis remain ill defined. Using a GC mouse model driven by hyperactivation of the signal transducer and activator of transcription (STAT)3 oncogene, we show that STAT3 directly upregulates the epithelial expression of the inflammatory mediator Toll-like receptor (TLR)2 in gastric tumors. Genetic and therapeutic targeting of TLR2 inhibited gastric tumorigenesis, but not inflammation, characterized by reduced proliferation and increased apoptosis of the gastric epithelium. Increased STAT3 pathway activation and TLR2 expression were also associated with poor GC patient survival. Collectively, our data reveal an unexpected role for TLR2 in the oncogenic function of STAT3 that may represent a therapeutic target in GC.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23079657     DOI: 10.1016/j.ccr.2012.08.010

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  102 in total

Review 1.  Microbiota in cancer development and treatment.

Authors:  Muhammad Hassan Raza; Kamni Gul; Abida Arshad; Naveeda Riaz; Usman Waheed; Abdul Rauf; Fahad Aldakheel; Shatha Alduraywish; Maqbool Ur Rehman; Muhammad Abdullah; Muhammad Arshad
Journal:  J Cancer Res Clin Oncol       Date:  2018-12-12       Impact factor: 4.553

2.  Signalling: New roles for TLR2.

Authors:  Gemma K Alderton
Journal:  Nat Rev Immunol       Date:  2012-12       Impact factor: 53.106

3.  Signalling: New roles for TLR2.

Authors:  Gemma K Alderton
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

4.  Glioma-associated microglial MMP9 expression is upregulated by TLR2 signaling and sensitive to minocycline.

Authors:  Feng Hu; Min-Chi Ku; Darko Markovic; Omar Dildar a Dzaye; Seija Lehnardt; Michael Synowitz; Susanne A Wolf; Helmut Kettenmann
Journal:  Int J Cancer       Date:  2014-05-09       Impact factor: 7.396

5.  CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer.

Authors:  Ming T Cheah; James Y Chen; Debashis Sahoo; Humberto Contreras-Trujillo; Anne K Volkmer; Ferenc A Scheeren; Jens-Peter Volkmer; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

Review 6.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions.

Authors:  Hua Yu; Heehyoung Lee; Andreas Herrmann; Ralf Buettner; Richard Jove
Journal:  Nat Rev Cancer       Date:  2014-11       Impact factor: 60.716

7.  Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.

Authors:  A Miller; L McLeod; S Alhayyani; A Szczepny; D N Watkins; W Chen; P Enriori; W Ferlin; S Ruwanpura; B J Jenkins
Journal:  Oncogene       Date:  2016-11-28       Impact factor: 9.867

Review 8.  Role of the tumor microenvironment in the pathogenesis of gastric carcinoma.

Authors:  Hye Won Chung; Jong-Baeck Lim
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 9.  The gastrointestinal tumor microenvironment.

Authors:  Michael Quante; Julia Varga; Timothy C Wang; Florian R Greten
Journal:  Gastroenterology       Date:  2013-04-10       Impact factor: 22.682

Review 10.  The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms.

Authors:  Kosuke Mima; Shuji Ogino; Shigeki Nakagawa; Hiroshi Sawayama; Koichi Kinoshita; Ryuichi Krashima; Takatsugu Ishimoto; Katsunori Imai; Masaaki Iwatsuki; Daisuke Hashimoto; Yoshifumi Baba; Yasuo Sakamoto; Yo-Ichi Yamashita; Naoya Yoshida; Akira Chikamoto; Takatoshi Ishiko; Hideo Baba
Journal:  Surg Oncol       Date:  2017-07-21       Impact factor: 3.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.